Zoetis IncNYSE: ZTS
Health Care · Pharmaceuticals
$78.89
-0.55%
Vol: 136K
Research Digest
Wednesday, June 17, 2026
A securities fraud class action against Zoetis was publicized June 15 following weak prescription trends and guidance cuts.
On June 15, 2026, law firms including Levi & Korsinsky publicized a securities class action lawsuit against Zoetis on behalf of investors, with a July 27, 2026 lead-plaintiff deadline. The suit follows the company's disclosures of weaker veterinarian prescription trends, market-share pressure, and lowered guidance that drove a sharp stock pullback. Management has attributed underperformance to increased pet-owner price sensitivity, lower veterinary clinic traffic, and intensifying competition in key pet-care categories. Analysts have been split, trimming average price targets by roughly $30-40 toward the low $100s while several maintain Buy ratings. The bear case is mounting legal overhang layered on top of decelerating organic growth and competitive erosion in core franchises.
Previous Market Intelligence
13 daysJun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Zoetis cuts 2026 guidance on weak US pet demand; shares plunged 21.5%Negative▶
Q1 revenue $2.26B (+3%), net income $601M, EPS $1.42 — missed estimates. Lowered FY26 guidance to $9.68-9.96B revenue and adj EPS $6.85-7.00, citing pet owner price sensitivity, fewer vet visits, rising competition in companion animal. Shares fell $23.91 (-21.5%) to $87.31 on May 7. Multiple analyst PT cuts: Citi $112 from $145, UBS $99 from $130, Stifel $105 from $130, JPMorgan $130 from $190. Securities fraud investigations launched by Levi & Korsinsky and Howard G. Smith. Declared $0.53 Q3 dividend.
May 20Zoetis shares rose 4.7% on May 18 to $77.72, attempting a recovery from the post-earnings selloff, while a securities fraud investigation by Howard G. Smith law office was disclosed targeting shareholders who lost money after the May 7 guidance cut.Mixed▶
On May 18, 2026, Zoetis (ZTS) shares rallied 4.7% to $77.72 as the stock attempted to stabilize after the steep post-earnings drop. The Law Offices of Howard G. Smith publicly invited Zoetis shareholders who lost money to participate in a securities fraud investigation tied to the company's Q1 results and guidance cut. On May 7, Zoetis lowered full-year 2026 revenue guidance to $9.68-9.96B citing weaker U.S. companion animal demand, fewer vet visits, and pricing pressure, which sent shares down 21.5% in a single session. The legal investigation introduces additional overhang on the stock just as it tries to recover. Risk remains elevated as litigation could distract management and result in disclosure scrutiny.
May 19Zoetis (ZTS) named in securities-fraud investigation announced May 18, 2026 by Law Offices of Howard G. Smith after May 7 guidance-cut share crash.Negative▶
On May 18, 2026, the Law Offices of Howard G. Smith disclosed a securities-fraud investigation into Zoetis on behalf of investors who lost money, following the May 7 selloff in which ZTS dropped 21.5% to $87.31 after the company cut FY26 guidance citing weaker U.S. companion-animal demand. Shares partially rebounded 4.7% to $77.72 on May 18. This matters because shareholder-litigation overhang adds legal-cost and disclosure risk on top of the already-impaired pet-health growth thesis. Bear case: multiple analysts (UBS to $99, Stifel to $105, JPMorgan to $130) slashed targets; demand softness may persist into H2 2026.
May 18Zoetis hit a 52-week low after Levi & Korsinsky launched a securities fraud investigation following the Q1 miss and guidance cutNegative▶
Zoetis shares are down ~10.4% on the week and roughly 33% from May 6 levels following its Q1 2026 earnings miss and lowered full-year revenue guidance to $9.68-$9.96B. Law firm Levi & Korsinsky announced a securities fraud investigation over the May 7 disclosures, in which CEO Kristin Peck called the quarter 'more challenging' than expected. Companion animal product sales fell 11% on weaker U.S. pet demand, increased price sensitivity, fewer vet visits, and stiffer competition in dermatology and parasiticides. The stock approached a 52-week low heading into Monday's open, with multiple analysts cutting price targets. Bright spots included 12% livestock growth, 10% international growth, and a pending Neogen animal genomics acquisition expected to close in H2 2026.
May 15Zoetis shares hit 52-week low near $74 as Q1 2026 miss and guidance cut trigger multiple analyst price-target reductionsNegative▶
Zoetis reported Q1 2026 revenue of $2.26B (miss vs $2.31B est) and adjusted EPS of $1.53 (vs $1.62 est) on May 7, then cut full-year 2026 revenue guidance to $9.82B midpoint from $9.93B. U.S. companion animal sales fell 11% organically due to generic competition pressuring legacy drugs Convenia and Cerenia plus softer dermatology/pain franchise demand. Shares collapsed ~21.5% on the print and continue to make new 52-week lows around $74.29, down 37% YTD. UBS, Stifel, and JPMorgan cut price targets sharply, citing structural concerns about whether weakness is cyclical or generics-driven. Director Michael McCallister made an insider purchase, offering one bullish signal. Levi & Korsinsky has opened a securities fraud investigation tied to the guidance cut.
May 14Zoetis faces securities fraud investigation after May 7 earnings miss and guidance cut sent shares down 24%.Negative▶
Levi & Korsinsky announced on May 13, 2026 a securities fraud investigation into Zoetis after Q1 2026 results triggered a roughly 24% stock decline on May 7. The company reported Q1 sales of $2.262B with an 8% drop in U.S. pet healthcare revenue, citing increased price sensitivity, fewer vet visits, and generic competition impacting legacy drugs Convenia and Cerenia. Zoetis cut full-year 2026 guidance to $9.68-9.96B revenue and $2.68-2.76B net income. Stock fell roughly $23.91 per share on May 7 to $82.83, with shares more recently trading near $75.26. UBS lowered its price target to $99 from $130, keeping Neutral. Livestock and international sales grew 12% and 10% respectively, offsetting some U.S. companion animal weakness.
May 13Zoetis shares are down ~24% after the company missed Q1 estimates and cut full-year 2026 guidance on weaker U.S. pet demand and intensifying competition.Negative▶
Zoetis reported Q1 2026 results on May 7, missing both top- and bottom-line estimates: revenue of $2.26 billion (vs. $2.33B est.) and EPS of $1.53 (vs. $1.63 est.). The company cut its full-year 2026 revenue guidance to $9.68-$9.96 billion and net income guidance to $2.68-$2.76 billion. U.S. companion animal sales declined ~11% YoY on softer end-market demand and heightened competition, particularly affecting the dermatology franchise and Simparica Trio. Management cited increased pet-owner price sensitivity, fewer vet visits, and rising generic and competitive pressure as structural factors weighing on results. Shares plunged ~13% in premarket trade on the report and have fallen approximately 24% over the surrounding period, prompting a broad reassessment of whether the slowdown is cyclical or structural.
May 12Zoetis stock plunges 24% after Q1 miss and 2026 guidance cut on softer U.S. companion animal demandNegative▶
Zoetis shares are down ~24% after reporting Q1 2026 earnings on May 7 with $1.53 EPS missing $1.63 estimates and revenue of $2.26B missing by $66M. Companion animal product sales dropped 11% on weaker demand and rising competition, with key dermatology franchise and Simparica Trio facing competitive pressure and macro price sensitivity. Management lowered full-year 2026 guidance to $9.68-9.96B revenue and $2.68-2.76B net income. Stock dropped to $77.61 from prior levels, hitting a 6-day losing streak. Zoetis agreed to acquire Neogen's animal genomics business to strengthen its livestock genetics portfolio.
May 11Zoetis shares drop ~13% premarket after Q1 EPS miss and 2026 guidance cut on weaker US companion animal demand; multiple analysts slash targetsNegative▶
Zoetis posted Q1 2026 EPS of $1.53 vs. estimates of $1.63, with revenue of $2.26 billion missing estimates of $2.33 billion. Shares fell roughly 13% in premarket trading on May 7 after the company lowered full-year 2026 guidance to revenue of $9.68-9.96 billion and adjusted EPS of $6.85-7.00. Management cited increased price sensitivity among pet owners, fewer veterinary visits, and rising generic competition impacting legacy drugs Convenia and Cerenia. Multiple analysts cut targets: UBS to $99 from $130, Stifel to $105 from $130, and JPMorgan to $130 from $190. The Neogen acquisition is still expected to close in H2 2026. This raises structural concerns about US companion animal market dynamics and competitive moat erosion.
May 8Zoetis plummets 21% on Q1 miss; cuts guidance citing pet owner price sensitivityNegative▶
Zoetis stock crashed 21% after Q1 2026 earnings disappointment: EPS of $1.53 missed $1.60 estimate, revenue of $2.26B missed $2.3B consensus. U.S. companion animal revenue fell 8%, with product sales down 11% due to pet owner price sensitivity and reduced vet visits. CEO cited increased competitive pressure in generics (Convenia, Cerenia). Company lowered FY2026 EPS guidance to $6.85–$7.00 from $7.00–$7.10 and revenue to $9.68–$9.96B. Adjusted operating margin deteriorated 6.4 ppts to 33.5%, a sharp decline that rattled investors. Demand softness and margin compression signal headwinds in pet healthcare spending. Analyst sentiment turned cautious despite "Buy" ratings reflecting execution uncertainty. Stock at $88.62 faces longer-term recovery risk.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $1,113.86 | -0.77% | +13.6% | 25.2x | 0.52 | $1.00T |
| JNJJOHNSON | $233.15 | -0.86% | +2.7% | 18.5x | 0.26 | $566.1B |
| MRKMERCK | $114.57 | -0.52% | +2.3% | 12.0x | 0.22 | $284.4B |
| PFEPFIZER | $25.94 | -0.38% | +2.8% | 9.2x | 0.29 | $148.4B |
| BMYBRISTOL | $55.84 | -0.14% | -2.4% | 9.1x | 0.24 | $114.2B |
| ZTSZOETIS | $78.89 | -0.55% | +2.1% | 10.7x | 0.74 | $33.3B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.